Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Technology appraisal
Summary (source: NICE)
Reference: TA305
Type: Technology appraisal
Published: 26 February 2014
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion is technology appraisal TA305, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 26 February 2014. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.